RCM
ADMS

Riverhead Capital Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Riverhead Capital Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,000
Closed -$60K – 1583
2018
Q3 		$60K Buy
+3,000
New +$70.4K ﹤0.01% 1469

Other funds holding ADMS

Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Riverhead Capital Management's ADMS Position: Q4 2018 in Review

Riverhead Capital Management sold out of Adamas Pharmaceuticals (ADMS) in Q4 2018, closing a stake of 3,000 shares — an estimated $60K sold.

Riverhead Capital Management first reported a position in ADMS in Q3 2018 and held it in 1 quarter. The position peaked at $60K in Q3 2018. 98 funds tracked by Wall St. Rank hold ADMS as of Q4 2018.

  • Riverhead Capital Management reported no remaining Adamas Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Riverhead Capital Management sold 3,000 Adamas Pharmaceuticals shares in Q4 2018, an estimated $60K.
  • Riverhead Capital Management first reported a position in Adamas Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Riverhead Capital Management's Adamas Pharmaceuticals position peaked at $60K in Q3 2018.
  • 98 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2018.

Based on Riverhead Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.